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Abstract: Dry and eczema-prone skin conditions such as atopic dermatitis and xerotic eczema
primarily indicate an impaired skin barrier function, which leads to chronic pruritus. Here, we
investigated the effects of a novel emollient containing H.ECMTM liposome, which contains a soluble
proteoglycan in combination with hydrolyzed collagen and hyaluronic acid. A prospective, single-
arm study was conducted on 25 participants with mild atopic dermatitis or dry skin to assess
the hydration and anti-inflammatory effect of the novel emollient applied daily over four weeks.
All efficacy parameters, including itching severity, transepidermal water loss, and skin hydration,
improved significantly after four weeks. The in vitro and ex vivo studies confirmed the restoration
of the skin’s barrier function. The study revealed the clinical and laboratory efficacy of H.ECMTM
liposome in reducing itching and improving the skin’s barrier integrity. Thus, the use of H.ECMTM
liposome can be considered a therapeutic option for dry and eczema-prone skin.
Keywords: dry skin; eczema; proteoglycan; skin barrier; liposome; hydration
1. Introduction
Skin, the largest organ, is in constant contact with the external environment and
forms a protective barrier against water loss. Usually, young and well-moisturized normal
skin is less susceptible to environmental injuries and infection. Therefore, itching and
inflammation associated with dry skin and eczema are less likely to occur [1]. Dry skin is
a common condition in which the capacitance of the skin is reduced owing to a decrease
in skin barrier function, affecting approximately 20% of children and 30–75% adults over
the age of 60 years [2]. Dry and eczema-prone skin is frequently the result of ageing or
specific conditions such as atopic dermatitis or hemodialysis [1]. Atopic dermatitis is
a representative, chronic, relapsing inflammatory skin disease characterized by itching,
eczema, and xerosis. Increasing evidence suggests that skin barrier dysfunction is an
etiological contributor to the development of atopic dermatitis [3]. The skin can also
lose epidermal barrier function when irradiated by ultraviolet light (UV) light and shows
markedly increased transepidermal water loss (TEWL), which eventually results in dry,
photoaged skin [4,5].
Proteoglycan (PG) is a constituent of the extracellular matrix and is widely distributed
in connective tissues such as skin, bone, cartilage, and the vascular wall forming complexes
with collagen, fibronectin, laminin, and hyaluronic acid (HA) [6]. It has been shown
that PG extracted from salmon nasal cartilage is a potent suppressor of inflammatory
responses induced by heat-killed Escherichia coli in mouse macrophages [7]. The PG is
usually extracted from salmon nasal cartilage, a byproduct of salmon processed foods,
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making its production environmentally advantageous. PG modulates the inflammatory
state of infected wounds and promotes wound healing in mice [8]. PGs bind with HA
to form multi-molecular aggregates in cartilage and provide matrix binding sites and
cell surface receptors for growth factors such as fibroblast growth factors [9]. PGs also
possess epidermal growth factor-like domain, which are modular components of larger
proteins with growth factor activity [9]. Therefore, PGs may enhance the skin barrier
function and wound healing by playing a role in anti-inflammatory function, modulating
the proliferative activity of fibroblasts, and promoting matrix binding by growth factors.
Various skincare products have been developed to maintain and improve the skin
barrier function and increase its water content. In this study, we investigated the efficacy
of the novel nanoliposome formulation comprising soluble proteoglycan combined with
HA and hydrolyzed collagen in restoring the skin barrier function in patients with mild
atopic dermatitis and dry skin. We investigated whether soluble proteoglycan synergized
the effects of HA and hydrolyzed collagen, both of which are the well-known major
constituents of the extracellular matrix that improve skin water content, TEWL, and skin
elasticity [10,11]. We performed a prospective, single-arm clinical trial on 25 Asian patients
with mild atopic dermatitis or dry skin to evaluate the effects of the H.ECMTM liposome-
containing emollient comprising the soluble proteoglycan mixed with HA and hydrolyzed
collagen. Moreover, in vitro and human ex vivo experiments were conducted to explore
the pathophysiologic mechanism by which the H.ECMTM liposome-containing emollient
enabled the restoration of skin barrier function and hydration.
2. Results
2.1. Patient Characteristics
The clinical study was conducted on 25 Asian patients, aged 19 years or older, with
mild atopic dermatitis and dry skin. The mean age of the participants was 40.7 ± 11.5
years (range, 20–56 years). Four participants were male, while 21 participants were female.
Seven participants were diagnosed with mild atopic dermatitis, while the remaining 18
patients had xerotic skin with a xerosis assessment scale (XAS) score greater than 2. Two of
the participants dropped out due to non-compliance. In the final analysis, data from 23
participants were collected and analyzed. The patients’ demographic data are presented in
Supplementary Table S1.
2.2. Clinical Efficacy of a Topical Proteoglycan Product Combined with HA and Collagen
The participants applied the H.ECMTM liposome-containing emollient twice daily onto
their skin lesions for 4 weeks. The improvement of the skin barrier function was measured
primarily by evaluating TEWL. The TEWL decreased significantly from 26.47 ± 7.36 to
17.00± 7.30 at week 2, and 17.43± 6.35 at week 4 (Figure 1A, *** p < 0.005, t-test). Moreover,
the level of skin hydration measured using the Corneometer showed significant improve-
ment at weeks 2 and 4 over the baseline. The baseline skin hydration was 30.78 ± 8.24, and
it increased to 51.04 ± 10.54 and 56.34 ± 11.57 at weeks 2 and 4, respectively (Figure 1B,
*** p < 0.005, t-test). The degrees of erythema were assessed according to the erythema
index using Mexameter, and the index values were 220.00 ± 95.55, 207.56 ± 70.18, and
182.95 ± 62.91 at baseline, week 2, and week 4, respectively (Figure 1C). However, the
difference in the degree of erythema before and after the treatment was not statistically
significant.
The primary outcome for comparing the symptom severity before and after treatment
was assessed by the difference in the verbal rating scale (VRS) on itching. Compared to
the baseline average VRS of moderate itching (1.78 ± 0.42), VRS decreased significantly
to mild itching (0.60 ± 0.50) at week 2, and mild to almost no itching (0.23 ± 0.42) at
week 4 (Figure 1D, *** p < 0.005, t-test). The average global improvement assessment score
(GIS) at the same time points as assigned by three blinded, independent investigators
was 1.84 ± 0.76 (marked improvement), while the average GIS by the participants was
1.48 ± 0.51 (near-total improvement; Figure 2).
Int. J. Mol. Sci. 2021, 22, 10189 3 of 12













Figure 1. Changes in the biophysic l r eters and itching after four-week application of the H.ECMTM liposome-
containing emollient. The evaluations for (A) transepidermal water loss (TEWL), (B) skin hydration (using Corneometer),
(C) erythema index, and (D) VRS (verbal rating scale) showed improvements after the application of the H.ECMTM
liposome-containing emollient. *** p < 0.005.
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and AQP3 genes  involved  in skin hydration were compared with  those  in response  to 
treatment with 1 μM retinoic acid (positive control) using KCs. The expression levels of 
HAS3 and AQP3 in the 0.05% H.ECMTM liposome treatment group increased significantly 
Figure 2. I ages showing im rovement of skin hydration and erythema after four weeks of
H.ECMTM liposome-containing emollient application (subject examples S01, S06, S07, and S17).
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No adverse events were observed during the four-week study period. None of the
participants dropped out of the study because of adverse events, suggesting that the topical
H.ECMTM liposome formulation was safe to use.
2.3. In Vitro Evaluation of H.ECMTM Liposome and Its Efficacy on Skin Barrier Function and Wrinkles
To measure if H.ECMTM liposome-containing emollient was cytotoxic, an MTT assay
was performed using a mouse macrophage (RAW 264.7), human epidermal keratinocyte
(KC), and human dermal fibroblast (HDF) cells. All cell lines were treated with 0.01%,
0.05%, 0.1%, 0.5%, and 1% H.ECMTM liposomes, and the results of the MTT assay are
shown in comparison with those of the control cells. Additionally, the cytotoxicity of
lipopolysaccharide (LPS; 0.5–50 µg/mL) was evaluated in HDF cells. The results of the MTT
assay for each cell line are shown in Supplementary Figure S1. Based on the results, 0.05%
H.ECMTM liposome treatment was used in the real-time quantitative reverse transcription
polymerase chain reaction (qRT-PCR) and immunofluorescence staining experiments.
Gene expression levels were evaluated using qRT-PCR. The expressions of the HAS3
and AQP3 genes involved in skin hydration were compared with those in response to
treatment with 1 µM retinoic acid (positive control) using KCs. The expression levels
of HAS3 and AQP3 in the 0.05% H.ECMTM liposome treatment group increased signif-
icantly in comparison to those in the negative control group (* p < 0.05, ** p < 0.01, ***
p < 0.005; Figure 3A,B). Notably, the expression level of AQP3 in the H.ECMTM liposome-
treated group was significantly higher than that in the positive control group (*** p < 0.005,
Figure 3A). Additional immunofluorescence staining of filaggrin in KCs treated with
1.8 mM calcium (positive control) revealed that treatment with H.ECMTM liposome signifi-
cantly increased the expression level of filaggrin compared to that of the negative control
group (** p < 0.01, *** p < 0.005; Figure 3C).
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Figure 3. Expression levels of the AQP3 and HAS3 genes and the comparison of filaggrin expression
via immunofluorescence staining using KCs. The expression of genes encoding skin hydration factors
such as AQP3 (A) and HAS3 (B) were induced in the 0.05% H.ECMTM liposome treatment group
more than in the negative cont ol group; 1 µM retinoic a id treatm nt was used as a positive control.
Treatment with 0.05% H.ECMTM liposome induced filaggrin expression more significantly than the
negative control (C) 1.8 mM calcium treatment was use as a positive control. Scale bar indicated
100 µm. * p < 0.05, ** p < 0.01, *** p < 0.005.
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Next, we performed ELISA to measure the TNF-α levels induced by the LPS treatment
(2 µg/mL) of RAW 264.7 cells; dexamethasone (1 µM) was used as the positive control.
When treated with H.ECMTM liposome, the TNF-α levels were lower than in the negative
control group (* p < 0.05, *** p < 0.005, Figure 4A). Collectively, these results suggest
that H.ECMTM liposome treatment enhances the skin barrier function and hydration and
simultaneously exerts anti-inflammatory effects.
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Figure 4. Variations in the expression levels of tumor necrosis factor (TNF) –α expression bet een the negative control, 1
µM Dexamethasone treatment and 0.05% H.ECMT liposome groups compared to the LPS-treated RAW 264.7 cells (A)
Expression levels of COL1A1 and MMP1 genes. The expression levels of COL1A1 (B) and MMP1 (C), representing the
expression of wrinkle-related factors, improved with 0.05% H.ECMTM liposome treatment compared to the negative control
group of HDF cells (B). The 10 ng/mL recombinant EFG treatment was used as a positive control. * p < 0.05, ** p < 0.01, ***
p < 0.005.
Lastly, the mRNA expression levels of the COL1A1 and MMP1 genes associated with
skin aging and wrinkles were analyzed using HDF cells. Recombinant EGF was used
as the positive control. In comparison with the negative control group, the expression
level of COL1A1 significantly increased in the H.ECMTM liposome-treated group, while
the expression of MMP1 decrease , indicati t at H.ECMTM liposome treatment exerts
anti-aging effects on skin and reduce wrinkles (** p < 0.01, *** p < 0.005, respe tively;
Figure 4B,C).
2.4. Ex Vivo Study on the Effect of H.ECMTM Liposomes on Skin Barrier Function and Hydration
The qRT-PCR and immunofluorescence staining were performed using an ex vivo
model of human skin tissue to confirm the changes in the expression of the factors related
to the skin barrier function and skin hydration upon application of the H.ECMTM liposome.
All experiments were conducted using three replicates of two different concentrations, 0.1%,
and 0.2%. The qRT-PCR results indicated that UVB-irradiation significantly reduced the
expression of not only filaggrin and loricrin but also the HAS3 and AQP3 genes associated
with the skin barrier function (* p < 0.05, ** p < 0.01, *** p < 0.005; Figure 5). Treatment with
0.1% H.ECMTM liposome enhanced the gene expression of filaggrin, loricrin, HAS3, and
AQP3 (* p < 0.05, ** p < 0.01, *** p < 0.005; Figure 5A). Furthermore, treatment with 0.2%
H.ECMTM liposome after UVB-irradiation significantly increased the expression of loricrin,
HAS3, and AQP3 (* p < 0.05, *** p < 0.005; Figure 5B).
In addition, the protein expression levels for filaggrin and loricrin proteins were mea-
sured via immunofluorescence staining (Figure 6A,B). Supplementary Figure S2 shows the
results of the t-tests after qRT-PCR in the ex vivo study. After 300 mJ/cm2 UVB-irradiation,
the filaggrin and loricrin expression was reduced, but increased significantly after treatment
with 0.1% and 0.2% H.ECMTM liposome (* p < 0.05, ** p < 0.01, *** p < 0.005; Figure 6C).
Consistent with the qRT-PCR results, 0.1% H.ECMTM liposome treatment enhanced filag-
grin and loricrin expression more than the 0.2% H.ECMTM liposome treatment. The results
from the ex vivo study correlated well with the in vitro data, suggesting that H.ECMTM
liposome enhanced both the skin barrier function and hydration in damaged skin.
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Figure 5. Expression levels of filaggrin, loricrin, HAS3, and AQP3 genes in untreated tissue specimen (negative control), and
only UVB irradiated (UV), 0.1% (UV + 0.1%) and 0.2% (UV + 0.2%) H.ECMTM liposome treatm nt in UVB-irradiated issue
specimens. Expressions of genes encoding the factors related to the skin barrier function such as the filaggrin and loricrin
were induced in the 0.1% and 0.2% H.ECMTM liposome treatment groups more than the UV group (A). The expression
levels of genes COL1A1 and MMP1 encoding skin hydration factors were higher in the 0.1% and 0.2% H.ECMTM liposome
treatments than the UV group (B). * p < 0.05, ** p < 0.01, *** p < 0.005.










































Figure 6. Comparison of filaggrin (A) and loricrin (B) expression using immunofluorescence staining. Treatments with 0.1%
(UV + 0.1%) and 0.2% (UV + 0.2%) H.ECMTM liposome increased the expression of filaggrin and loricrin that were reduced
by UVB irradiation. Moreover, the expression after 0.1% H.ECMTM liposome treatment was significantly higher than with
0.2% H.ECMTM liposome (C). Scale bar indicat d 100 µm. ** p < 0.01, *** p < 0.005.
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3. Discussion
Various topical emollients containing diverse, active ingredients have been used to
treat dry, eczema-prone skin caused by atopic dermatitis and xerotic eczema [12]. However,
limited information is available on the effect of soluble proteoglycans on restoring the skin
barrier function via enhancement of hydration and reduction of skin inflammation. PGs
and glycosaminoglycans (GAGs) are the major components of the extracellular matrix,
along with collagen. HA is one of the known GAGs that form proteoglycan aggregates,
which crosslink with other matrix proteins such as collagen, constituting supermolecular
structures that increase skin firmness [13]. Previous studies on proteoglycans, HA, and
collagen have focused on their anti-aging and anti-wrinkle effects [13–20].
Oral and topical formulations of collagen and HA have become increasingly available
in the cosmeceutical market. Studies have shown that oral intake of collagen peptides
attenuates UVB irradiation-induced skin dehydration by regulating HA synthesis [21].
Moreover, a clinical and ex vivo study showed that oral collagen peptide supplementation
enhanced skin moisture and dermal collagen density [22]. A study in hairless mice also
revealed that collagen hydrolysate intake mitigated the loss of epidermal barrier function
and skin elasticity induced by ultraviolet radiation [23], confirming the role of collagen
supplements in restoring the skin barrier function. Oral HA has also been shown to relieve
wrinkles and dry skin in long-term clinical studies [24]. The effect of HA on collagen
synthesis has also been explored in in vitro and in vivo studies [25].
In this study, we aimed to investigate the effect of a soluble proteoglycan combined
with HA and hydrolyzed collagen on the restoration of the skin barrier function and
hydration. We designed a four-week, single-arm prospective clinical trial of an emollient
containing H.ECMTM liposomes to observe its effect on mild atopic dermatitis and dry
skin in participants. The participants showed statistically significant improvements in not
only clinical symptoms (including itching), but also in objective biophysical parameters,
including TEWL and the Corneometer measurement. The GIS evaluated at the end of the
study revealed notable efficacy of the H.ECMTM liposome-containing emollient on dry and
eczema-prone skin.
Furthermore, our in vitro and ex vivo experiments revealed that the treatment of KCs
with H.ECMTM liposome promoted the mRNA expression of HAS3 and AQP3, the factors
influencing skin hydration. Immunofluorescence staining of KCs showed the increased
expression of filaggrin upon treatment with the H.ECMTM liposome-containing emollient,
suggesting its role in enhancing the skin barrier function. The ex vivo experiments pro-
vided consistent results, revealing increased mRNA expression of HAS3, AQP3, filaggrin,
and loricrin upon treatment with H.ECMTM liposome in UVB-irradiated human skin. Im-
munofluorescence staining suggested that the expression of filaggrin and loricrin, the major
constituent proteins of the epidermal skin barrier [26,27], also increased significantly after
H.ECMTM liposome treatment.
In addition, we investigated the difference in the expression of TNF-α upon H.ECMTM
liposome treatment using mouse macrophages. TNF-α is known to downregulate filag-
grin and loricrin expression, thereby affecting the skin barrier function [28]. Treatment
with H.ECMTM liposome significantly decreased the expression of TNF-α, indicating its
anti-inflammatory function and concomitantly improved the skin barrier. Lastly, in vitro
experiments using HDFs showed significantly increased expression of COL1A1 and MMP-1,
implying anti-aging and anti-wrinkle formation effects of H.ECMTM liposomes.
In conclusion, our clinical and laboratory experiments demonstrated the effects of
H.ECMTM liposomes on the restoration of the skin barrier function in atopic dermatitis and
dry skin. Nonetheless, the study has several limitations. First, it was a single-arm study
with a relatively small number of participants. Thus, randomized, placebo-controlled stud-
ies with larger populations are necessary to better advocate the benefits of the H.ECMTM
liposome-containing emollient. Secondly, although we have shown the changes in the
expression of factors related to skin barrier function, hydration, and anti-aging via in vitro
and ex vivo experiments, we did not explore the molecular pathways underlying changes
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in these factors. Further experimental studies need to investigate the pathophysiologic
mechanism of H.ECMTM liposomes in enhancing the skin barrier function and provide a
complete understanding of the effect of topical proteoglycans combined with hydrolyzed
collagen and HA on the skin.
4. Materials and Methods
4.1. Participants
The clinical study was conducted on 25 patients, aged 19 years or older, with mild
atopic dermatitis and dry skin, under informed consent. The study was conducted after
receiving approval from the Clinical Trial Review Committee of Severance Hospital, Yonsei
University College of Medicine (IRB number 1-2020-0063), in compliance with the ethi-
cal principles of the Declaration of Helsinki. No topical or systemic anti-inflammatory
treatments were administered 2 weeks prior to the inclusion of the patients in the study.
The inclusion criteria included patients previously diagnosed with mild atopic dermati-
tis (Eczema Area and Severity Index < 15) or dry skin with a Xerosis Assessment Scale
(XAS) [29] greater than 2 (0: absence of xerosis; 1: a few minute flakes, 2: many undif-
ferentiated skin flakes, 3: some polygonal scales; 4: a moderate number of polygonal
scales; 5: a large number of polygonal scales; 6: fissuring between scales; 7: moderate
deep fissuring between scales; 8: deep fissuring). Exclusion criteria included a history of
uncontrolled medical illness, pregnancy, and any form of dermatologic treatment (e.g.,
laser, filler, or tattoos) in the 3 months preceding the study. Patients with atopic dermatitis
who underwent systemic anti-inflammatory or immunosuppressive treatments within 1
month and those that received topical treatments or oral antihistamines within 2 weeks of
the study were also excluded.
4.2. Application of an H.ECMTM Liposome-Containing Emollient Containing Proteoglycan
Combined with Hyaluronic Acid and Collagen
The topical emollient investigated in this study contained 0.01% H.ECMTM liposomes,
a novel product composed of a soluble proteoglycan (900–1200 kDa) derived from salmon
nasal cartilage, emulsified with HA on its non-denatured N-terminus, and hydrolyzed
collagen. This composition was prepared in the form of nano-liposomes, which can easily
penetrate the skin with a diameter of 50–150 nm. The 25 participants included in the study
consented to apply the moisturizer to the skin lesions at least twice daily for 4 weeks to
evaluate the safety and efficacy of this emollient. To assess the safety, all participants were
asked to report any adverse events experienced while using the topical emollient.
4.3. Assessments for Clinical Efficacy
All patients were followed up at baseline, week 2, and week 4 after the initiation
of treatment. Standardized digital photographs were taken (Canon EOS 850D, Tokyo,
Japan) at each visit, and three independent investigators scored the outcomes on a 5-point
scale, GIS (grade 1, more than 75% = near-total improvement; grade 2, 51–75% = marked
improvement; grade 3, 26–50% = moderate improvement; grade 4, 0–25% = minimal
improvement; grade 5 = no improvement) and the subjects’ GIS were obtained based on
the clinical photographs at week 4. The clinical efficacy of the study product was also
investigated by biophysical parameters of TEWL, skin hydration, and skin erythema at each
visit. The skin barrier function and hydration were evaluated using a Corneometer® and
Tewemeter® (Courage Khazaka Electronic GmbH, Köln, Germany), while skin erythema
was measured using a Mexameter® MX 18 (Courage Khazaka Electronic GmbH, Köln,
Germany). The measurements were conducted after subjects were acclimatized to the
environment for 30 min at each visit under controlled environmental conditions (room
temperature: 18–21 ◦C relative humidity: 40–60%, without direct light). Finally, the
symptomatic improvement in the degree of itching was evaluated at each visit by the
participants via VRS (grade 0 = no itching, grade 1 = mild itching, grade 2 = moderate
itching, grade 3 = severe itching, 4 = very severe itching).
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4.4. Cell Culture
A mouse macrophage (RAW 264.7), a human epidermal keratinocyte (KC), and human
dermal fibroblast (HDF) cell lines were procured from ATCC® (Manassas, VA, USA) and
Thermo Fisher Scientific (Waltham, MA, USA). RAW 264.7 cells were cultured in Dulbecco’s
modified Eagle’s Medium (DMEM; Lonza, Walkersville, MD, USA) containing 10% (v/v)
fetal bovine serum (FBS; Gibco, Grand island, NY, USA) and 1% Penicillin-Streptavidin
(PS; Gibco) and KCs were cultured in KBMTM Gold Basal Medium (Lonza) containing
KGMTM Gold SingleQuotsTM supplements (Lonza). HDF cells were cultured in Roswell
Park Memorial Institute Medium (RPMI) 1640 (Lonza) supplemented with 10% FBS and
1% PS. All cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2.
4.5. Cell Cytotoxicity Measurement
Cell cytotoxicity was measured using the MTT assay. Briefly, each cell line (1 × 104
cells/well) was cultured in 48-well cell culture plates and treated with H.ECM™ liposome
(0.01–1%) when cells reached over 80% confluence. Additionally, HDF cells were treated
with LPS (0.5–50 µg/mL). After treatment, 200 µL MTT solution (diluted in each medium;
0.5 mg/mL) was added to the wells, and the cells were incubated at 37 ◦C for 4 h. Next,
200 µL dimethyl sulfoxide (DMSO) was added to each well, and 100 µL sample aliquot was
transferred to a 96-well plate. The absorbance at 585 nm was measured using an ELISA
microplate reader (VersaMax; Molecular Devices, California, CA, USA).
4.6. Enzyme-Linked Immunosorbent Assay
RAW 264.7 cells (2 × 104 cells/well) were seeded in 12-well plates and treated with
LPS (2 µg/mL; Sigma-Aldrich, Saint Louis, MO, USA) for inducing TNF-α expression when
cells reached more than 80% confluence. The cells were treated 0.1% H.ECM™ liposome
or 1 µM Dexamethasone (positive control; Sigma-Aldrich) and incubated for 24 h. Then,
the media used at culture was centrifuged at 2000× g for 10 min, and the supernatant was
used for ELISA. The Mouse TNF-α ELISA kit (Abcam, Cambridge, MA, USA) was used for
TNF-α measurement. ELISA was performed according to the manufacturer’s instructions.
The absorbance at 450 nm was measured using an ELISA microplate reader (VersaMax;
Molecular Devices, California, CA, USA).
4.7. Tissue Culture
The clinical trial was approved by the Institutional Review Board of Severance Hos-
pital, Yonsei University (IRB No. 4-2021-0262). For tissue culture, subcutaneous fat was
removed from human skin tissue, and the tissue was cut into 1 cm× 1 cm pieces. The tissue
specimens were placed into 6-well plates containing semi-solid DMEM and UVB-irradiated
at a dose of 300 mJ/cm2 using a UVB lamp (BLX26, BIO-LINK®-Crosslinker, FRA). The
surface of the irradiated tissue specimen was treated with 20 µL H-liposome at 0.1% and
0.2% concentrations and incubated at 37 °C in a humidified atmosphere containing 5%
CO2. The irradiation was conducted three times every 24 h. Each tissue specimen used in
the present experiment was obtained after 24 h of additional incubation.
4.8. Quantitative Reverse Transcription PCR
KCs (2 × 104 cells/well) and HDF cells (2 × 104 cells/well) were seeded into 12-well
plates and treated with 0.05% H.ECM™ liposome or positive control (1 µM retinoic acid
(Sigma-Aldrich) or 10 ng/mL recombinant epidermal growth factor (EGF; R&D systems,
Minneapolis, MN, USA) when the cells reached around 80% confluence. Then, the UVB-
irradiated human skin specimens were homogenized using TissueLyser II (Qiagen, Hilden,
Germany). Total RNA was extracted using the RNAiso Plus (Invitrogen, Waltham, MA,
USA) according to the manufacturer’s instructions. Total RNA was quantified using a
NanoDrop 2000 spectrophotometer (ThermoFisher) and reverse transcribed using an RNA
to cDNA EcoDry Premix Kit (Takara Sake, Berkley, CA, USA). The synthesized cDNA,
Taqman Gene Expression Master Mix (Applied Biosystems), and Taqman primer of each
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target (HAS3; Hs00193436_m1, AQP3; Hs00185020_m1, COL1A1: Hs00164004_m1, MMP1:
Hs00899658_m1; Filaggrin; Hs00856927_g1, Loricrin; Hs01894962_s1, Applied Biosystems)
were used for the qRT-PCR experiments. The expression level of each gene was normalized
to that of the housekeeping gene GAPDH (Hs02786624_g1, Applied Biosystems) and
calculated using the 2−∆∆Ct method.
4.9. Immunofluorescence Staining
In 8-well chamber slides, KCs (1 × 104 cells/well) were seeded and treated with
the positive control agent (1.8 mM calcium) or 0.05% H.ECM™ liposome when they
reached over 80% confluence and incubated for 24 h. For immunofluorescence, the 8-well
chamber slide containing treated KC cells and human skin cryosections (6 µm-thick) were
fixed at room temperature (20–25 ◦C) with 4% (w/v) paraformaldehyde (Cell Signaling
Technology, Danvers, MA, USA) for 15 min. Post-fixation, the chamber or cryosections were
washed with phosphate-buffered saline (PBS)-T (PBS containing Triton X-100; DAEJUNG,
Busan, KR) three times, followed by incubation with anti-filaggrin (ab81468; Abcam) or
nti-loricrin (ab85679; Abcam) antibodies overnight at 4 ◦C. After washing three times with
PBS-T, samples were incubated with the FITC-labeled secondary fluorescent antibody
(Goat pAb to Rb IgG-FITC, ab6717; Abcam) for 2 h at room temperature to bind primary
antibodies. Finally, the cells and tissue specimen were fixed using the fixation solution
(VECTASHIELD® mounting medium with 4′,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories Inc., Burlingame, CA, USA). All fluorescence images were acquired using a
laser-scanning microscope (LSM 700, Carl Zeiss, Jena, Germany), and fluorescence intensity
was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
4.10. Statistical Analysis
Data are presented as numbers (percentages) or means ± standard deviations. Data
sets were assessed for normality using the Kolmogorov–Smirnov test. Repeated-measures
analysis of variance and subsequent post hoc analysis by the Student’s t-test were performed
with Bonferroni’s correction to account for multiple comparisons. A p-value < 0.05 was
considered significant (* p < 0.05, ** p < 0.01, *** p < 0.005). All statistical analyses were
performed using SPSS version 25.0 (IBM Corp., Armonk, NY, USA). All laboratory exper-
iments were conducted at least three times (n ≥ 3), and the collected data was used for
statistical analyses.
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